Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): A Patient Guide

SAFETY WARNING: This guide is for educational purposes. Do not stop or change your rheumatoid arthritis or lung medications without consulting your care team. If you experience severe or rapidly worsening breathlessness, fainting, chest pain, blue lips, or inability to speak normally, seek emergency medical services immediately.

Rheumatoid arthritis is primarily known as a condition that affects the joints, but it is a systemic disease that can impact other parts of the body, including the lungs. Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD) occurs when the immune system begins to target the interstitium, the delicate tissue that surrounds the air sacs in your lungs ^[1]. This immune activity can lead to complex changes involving both inflammation and fibrosis (scarring), which is a thickening of the lung tissue that makes it harder for the lungs to expand and transfer oxygen into the bloodstream ^[2]. Imaging cannot always cleanly separate active inflammation from established scar tissue.

While imaging technology can often detect subtle lung changes in many people living with rheumatoid arthritis, it is important to remember that most of these findings do not progress to a point where they interfere with daily life. For many, the condition remains “subclinical,” meaning it may show up on a scan but does not cause noticeable symptoms like shortness of breath or a cough ^[3]. When symptoms do occur, they usually develop gradually, allowing you and your care team time to monitor the disease through breathing tests and imaging to determine if and when treatment is necessary ^[4]. In stable or subclinical cases, observation without immediate lung medication is an option.

Managing RA-ILD involves a dual approach designed to protect your lung function over the long term, depending on symptoms, extent, progression, and diagnostic confidence. Doctors may use medications called immunosuppressants to calm the underlying immune response and reduce inflammation ^[5]. If the disease shows a progressive fibrosing phenotype, a second class of medications known as antifibrotics may be considered to help slow down the formation of new scar tissue ^[6]. This “personalized” treatment plan is most effective when managed by a multidisciplinary team of rheumatologists and pulmonologists working together to balance the needs of your joints and your lungs ^[7].

While most changes in RA-ILD happen slowly, being proactive about your health is essential. The most critical part of living with this condition is recognizing that a sudden, rapid worsening of shortness of breath is not a routine “flare,” but a medical emergency known as an acute exacerbation, or could be driven by infection or blood clots ^[8]. By understanding the difference between the gradual, manageable nature of daily symptoms and the “red flags” of a sudden change, you can navigate your diagnosis with confidence. With modern monitoring and treatment strategies, the focus remains on preserving your quality of life and maintaining your ability to stay active ^[9].